Checkpoint Therapeutics (NASDAQ: CKPT)
$1.44
(-1.0%)
-$0.02
Price as of April 23, 2024, 4:00 p.m. ET
Checkpoint Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Checkpoint Therapeutics Company Info
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.
News & Analysis
Featured Article
Why Checkpoint Therapeutics Stock Is Heating Up Today
Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.
George Budwell | Jan 25, 2022
Featured Article
Why Checkpoint Therapeutics Skyrocketed Today
One analyst becomes a fervent believer in the company's stock.
Eric Volkman | Jun 9, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.